{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:51:05Z","timestamp":1787032265813,"version":"build-2736575974"},"reference-count":31,"publisher":"The Pediatric Pharmacy Association","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>The increasing use of carbapenems has contributed to a notable distribution of carbapenem-resistant Enterobacteriaceae (CRE). Recently, the incidence of CRE-associated infections is increasing significantly in NICUs, which pose a grave challenge to clinical treatment. We report 2 cases of IV ceftazidimeavibactam use to treat CRE infections in extremely premature neonates. The first case was diagnosed with bacteraemia and meningitis and the second one was diagnosed with bacteraemia only. Due to the lack of neonatal-specific information for IV ceftazidime-avibactam, the usual pediatric dose (62.5 mg\/kg\/dose every 8 hours) was used in these patients. Clinical cure occurred in these 2 patients. Although blood cultures became sterile after starting ceftazidime-avibactam in the second case, the patient died, presumably owing to sepsis or various causes, such as prematurity and chronic lung disease. Large and randomized studies are necessary to ensure the safety and efficacy of IV ceftazidime-avibactam for the treatment of neonates with sepsis caused by multidrug resistant organisms.<\/jats:p>","DOI":"10.5863\/1551-6776-27.2.192","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T17:41:51Z","timestamp":1644428511000},"page":"192-197","source":"Crossref","is-referenced-by-count":6,"title":["Intravenous Ceftazidime-Avibactam in Extremely Premature Neonates With Carbapenem-Resistant Enterobacteriaceae: Two Case Reports"],"prefix":"10.5863","volume":"27","author":[{"given":"Suzan S.","family":"Asfour","sequence":"first","affiliation":[{"name":"Clinical Pharmacy Department (SSA), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal A.","family":"Alaklobi","sequence":"additional","affiliation":[{"name":"Pediatric Infectious Disease Department (FAA), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adli","family":"Abdelrahim","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit (AA), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammed Y.","family":"Taha","sequence":"additional","affiliation":[{"name":"Pediatric Pharmacy Department (MYT), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raneem S.","family":"Asfour","sequence":"additional","affiliation":[{"name":"Pharmacy College (RSA), Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thanaa M.","family":"Khalil","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynaecology Department (TMK), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mountasser M.","family":"Al-Mouqdad","sequence":"additional","affiliation":[{"name":"Neonatal Intensive Care Unit (MMA), King Saud Medical City, Riyadh, Saudi Arabia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3883","reference":[{"issue":"suppl 1","key":"i2331-348X-27-2-192-b1","series-title":"J Infect","first-page":"S24","article-title":"Neonatal sepsis: progress towards improved outcomes","volume":"68","year":"2014","unstructured":"Shane\n              AL,\n            \n            \n              Stoll\n              BJ.\n            \n          \n          Neonatal sepsis: progress towards improved outcomes.\n\t\t\t\t\tJ Infect.\n\t\t\t\t\t2014;\n\t\t\t\t\t68(\n\t\t\t\t\tsuppl 1):\n\t\t\t\t\tS24\u2013\n\t\t\t\t\tS32."},{"issue":"10063","key":"i2331-348X-27-2-192-b2","series-title":"Lancet","first-page":"3027","article-title":"Global, regional, and national causes of under-5 mortality in 2000\u201315: an updated systematic analysis with implications for the Sustainable Development Goals","volume":"388","year":"2016","unstructured":"Liu\n              L,\n            \n            \n              Oza\n              S,\n            \n            \n              Hogan\n              D,\n            \n            \n              Chu\n              Y,\n            \n          \n          .\n\t\t\t\t\tGlobal, regional, and national causes of under-5 mortality in 2000\u201315: an updated systematic analysis with implications for the Sustainable Development Goals.\n\t\t\t\t\tLancet.\n\t\t\t\t\t2016;\n\t\t\t\t\t388(\n\t\t\t\t\t10063):\n\t\t\t\t\t3027\u2013\n\t\t\t\t\t3035."},{"issue":"2 pt 1","key":"i2331-348X-27-2-192-b3","series-title":"Pediatrics","first-page":"285","article-title":"Late-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network","volume":"110","year":"2002","unstructured":"Stoll\n              BJ,\n            \n            \n              Hansen\n              N,\n            \n            \n              Fanaroff\n              AA,\n            \n          \n          .\n\t\t\t\t\tLate-onset sepsis in very low birth weight neonates: the experience of the NICHD Neonatal Research Network.\n\t\t\t\t\tPediatrics.\n\t\t\t\t\t2002;\n\t\t\t\t\t110(\n\t\t\t\t\t2 pt 1):\n\t\t\t\t\t285\u2013\n\t\t\t\t\t291."},{"issue":"4","key":"i2331-348X-27-2-192-b4","series-title":"Semin Fetal Neonatal Med","first-page":"255","article-title":"Predictive monitoring for sepsis and necrotizing enterocolitis to prevent shock","volume":"20","year":"2015","unstructured":"Sullivan\n              BA,\n            \n            \n              Fairchild\n              KD.\n            \n          \n          Predictive monitoring for sepsis and necrotizing enterocolitis to prevent shock.\n\t\t\t\t\tSemin Fetal Neonatal Med.\n\t\t\t\t\t2015;\n\t\t\t\t\t20(\n\t\t\t\t\t4):\n\t\t\t\t\t255\u2013\n\t\t\t\t\t261."},{"issue":"2","key":"i2331-348X-27-2-192-b5","series-title":"Pediatr Res","first-page":"222","article-title":"Heart rate characteristics and clinical signs in neonatal sepsis","volume":"61","year":"2007","unstructured":"Griffin\n              MP,\n            \n            \n              Lake\n              DE,\n            \n            \n              O'Shea\n              TM,\n            \n            \n              Moorman\n              JR.\n            \n          \n          Heart rate characteristics and clinical signs in neonatal sepsis.\n\t\t\t\t\tPediatr Res.\n\t\t\t\t\t2007;\n\t\t\t\t\t61(\n\t\t\t\t\t2):\n\t\t\t\t\t222\u2013\n\t\t\t\t\t227."},{"key":"i2331-348X-27-2-192-b6","series-title":"Early Hum Dev","first-page":"83","article-title":"Vital signs analysis algorithm detects inflammatory response in premature infants with late onset sepsis and necrotizing enterocolitis","volume":"117","year":"2018","unstructured":"Mithal\n              LB,\n            \n            \n              Yogev\n              R,\n            \n            \n              Palac\n              HL,\n            \n          \n          .\n\t\t\t\t\tVital signs analysis algorithm detects inflammatory response in premature infants with late onset sepsis and necrotizing enterocolitis.\n\t\t\t\t\tEarly Hum Dev.\n\t\t\t\t\t2018;\n\t\t\t\t\t117:\n\t\t\t\t\t83\u2013\n\t\t\t\t\t89."},{"key":"i2331-348X-27-2-192-b7","series-title":"J Clin Neonatol","first-page":"141","article-title":"A retrospective cohort study patient chart review of neonatal sepsis investigating responsible microorganisms and their antimicrobial susceptibility","volume":"7","year":"2018","unstructured":"Al-Mouqdad\n              MM,\n            \n            \n              Aljobair\n              F,\n            \n            \n              Alaklobi\n              FA,\n            \n          \n          .\n\t\t\t\t\tA retrospective cohort study patient chart review of neonatal sepsis investigating responsible microorganisms and their antimicrobial susceptibility.\n\t\t\t\t\tJ Clin Neonatol.\n\t\t\t\t\t2018;\n\t\t\t\t\t7:\n\t\t\t\t\t141\u2013\n\t\t\t\t\t145."},{"issue":"1","key":"i2331-348X-27-2-192-b8","series-title":"J Pediatr Pharmacol Ther","first-page":"92","article-title":"The use of daptomycin in the treatment of persistent coagulase-negative staphylococcal sepsis in premature infants: a case series","volume":"26","year":"2021","unstructured":"Asfour\n              SS,\n            \n            \n              Asfour\n              RS,\n            \n            \n              Khalil\n              TM,\n            \n            \n              Al-Mouqdad\n              MM.\n            \n          \n          The use of daptomycin in the treatment of persistent coagulase-negative staphylococcal sepsis in premature infants: a case series.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2021;\n\t\t\t\t\t26(\n\t\t\t\t\t1):\n\t\t\t\t\t92\u2013\n\t\t\t\t\t98."},{"issue":"2","key":"i2331-348X-27-2-192-b9","series-title":"Pediatrics","first-page":"e322","article-title":"Risk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU","volume":"133","year":"2014","unstructured":"Tsai\n              MH,\n            \n            \n              Chu\n              SM,\n            \n            \n              Hsu\n              JF,\n            \n          \n          .\n\t\t\t\t\tRisk factors and outcomes for multidrug-resistant Gram-negative bacteremia in the NICU.\n\t\t\t\t\tPediatrics.\n\t\t\t\t\t2014;\n\t\t\t\t\t133(\n\t\t\t\t\t2):\n\t\t\t\t\te322\u2013\n\t\t\t\t\te329."},{"issue":"2","key":"i2331-348X-27-2-192-b10","series-title":"Diagn Microbiol Infect Dis","first-page":"115","article-title":"Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes","volume":"75","year":"2013","unstructured":"van Duin\n              D,\n            \n            \n              Kaye\n              KS,\n            \n            \n              Neuner\n              EA,\n            \n            \n              Bonomo\n              RA.\n            \n          \n          Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes.\n\t\t\t\t\tDiagn Microbiol Infect Dis.\n\t\t\t\t\t2013;\n\t\t\t\t\t75(\n\t\t\t\t\t2):\n\t\t\t\t\t115\u2013\n\t\t\t\t\t120."},{"issue":"2","key":"i2331-348X-27-2-192-b11","series-title":"Clin Infect Dis","first-page":"163","article-title":"Colistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae","volume":"66","year":"2018","unstructured":"van Duin\n              D,\n            \n            \n              Lok\n              JJ,\n            \n            \n              Earley\n              M,\n            \n          \n          .\n\t\t\t\t\tColistin versus ceftazidime-avibactam in the treatment of infections due to carbapenem-resistant Enterobacteriaceae.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t2018;\n\t\t\t\t\t66(\n\t\t\t\t\t2):\n\t\t\t\t\t163\u2013\n\t\t\t\t\t171."},{"issue":"2","key":"i2331-348X-27-2-192-b12","series-title":"J Pediatr Pharmacol Ther","first-page":"110","article-title":"Beyond susceptible and resistant, part III: treatment of infections due to Gram-negative organisms producing carbapenemases","volume":"21","year":"2016","unstructured":"Narayanan\n              N,\n            \n            \n              Johnson\n              L,\n            \n            \n              MacDougall\n              C.\n            \n          \n          Beyond susceptible and resistant, part III: treatment of infections due to Gram-negative organisms producing carbapenemases.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2016;\n\t\t\t\t\t21(\n\t\t\t\t\t2):\n\t\t\t\t\t110\u2013\n\t\t\t\t\t119."},{"issue":"6","key":"i2331-348X-27-2-192-b13","series-title":"Drugs","first-page":"675","article-title":"Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections","volume":"78","year":"2018","unstructured":"Shirley\n              M.\n            \n          \n          Ceftazidime-avibactam: a review in the treatment of serious Gram-negative bacterial infections.\n\t\t\t\t\tDrugs.\n\t\t\t\t\t2018;\n\t\t\t\t\t78(\n\t\t\t\t\t6):\n\t\t\t\t\t675\u2013\n\t\t\t\t\t692."},{"key":"i2331-348X-27-2-192-b14","series-title":"Front Med (Lausanne)","first-page":"74","article-title":"Treatment of infections due to MDR Gram-negative bacteria","volume":"6","year":"2019","unstructured":"Bassetti\n              M,\n            \n            \n              Peghin\n              M,\n            \n            \n              Vena\n              A,\n            \n            \n              Giacobbe\n              DR.\n            \n          \n          Treatment of infections due to MDR Gram-negative bacteria.\n\t\t\t\t\tFront Med (Lausanne).\n\t\t\t\t\t2019;\n\t\t\t\t\t6:\n\t\t\t\t\t74."},{"issue":"8","key":"i2331-348X-27-2-192-b15","series-title":"Pediatr Infect Dis J","first-page":"816","article-title":"Safety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children >\/=3 months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial","volume":"38","year":"2019","unstructured":"Bradley\n              JS,\n            \n            \n              Broadhurst\n              H,\n            \n            \n              Cheng\n              K,\n            \n          \n          .\n\t\t\t\t\tSafety and efficacy of ceftazidime-avibactam plus metronidazole in the treatment of children >\/=3 months to <18 years with complicated intra-abdominal infection: results from a phase 2, randomized, controlled trial.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2019;\n\t\t\t\t\t38(\n\t\t\t\t\t8):\n\t\t\t\t\t816\u2013\n\t\t\t\t\t824."},{"issue":"9","key":"i2331-348X-27-2-192-b16","series-title":"Pediatr Infect Dis J","first-page":"854","article-title":"Successful treatment of pandrug-resistant Klebsiella pneumoniae infection with ceftazidime-avibactam in a preterm infant: a case report","volume":"39","year":"2020","unstructured":"Coskun\n              Y,\n            \n            \n              Atici\n              S.\n            \n          \n          Successful treatment of pandrug-resistant Klebsiella pneumoniae infection with ceftazidime-avibactam in a preterm infant: a case report.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2020;\n\t\t\t\t\t39(\n\t\t\t\t\t9):\n\t\t\t\t\t854\u2013\n\t\t\t\t\t856."},{"issue":"4","key":"i2331-348X-27-2-192-b17","series-title":"Antimicrob Agents Chemother","first-page":"e02213","article-title":"Successful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam","volume":"62","year":"2018","unstructured":"Tamma\n              PD,\n            \n            \n              Fan\n              Y,\n            \n            \n              Bergman\n              Y,\n            \n          \n          .\n\t\t\t\t\tSuccessful treatment of persistent Burkholderia cepacia complex bacteremia with ceftazidime-avibactam.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2018;\n\t\t\t\t\t62(\n\t\t\t\t\t4):\n\t\t\t\t\te02213\u2013\n\t\t\t\t\t02217."},{"key":"i2331-348X-27-2-192-b18","series-title":"IDCases","first-page":"e00634","article-title":"Successful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient","volume":"18","year":"2019","unstructured":"Vargas\n              M,\n            \n            \n              Buonomo\n              AR,\n            \n            \n              Buonanno\n              P,\n            \n          \n          .\n\t\t\t\t\tSuccessful treatment of KPC-MDR septic shock with ceftazidime-avibactam in a pediatric critically ill patient.\n\t\t\t\t\tIDCases.\n\t\t\t\t\t2019;\n\t\t\t\t\t18:\n\t\t\t\t\te00634."},{"issue":"2","key":"i2331-348X-27-2-192-b19","series-title":"Antimicrob Agents Chemother","first-page":"e02463","article-title":"Successful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy","volume":"63","year":"2019","unstructured":"Hobson\n              CA,\n            \n            \n              Bonacorsi\n              S,\n            \n            \n              Fahd\n              M,\n            \n          \n          .\n\t\t\t\t\tSuccessful treatment of bacteremia due to NDM-1-producing Morganella morganii with aztreonam and ceftazidime-avibactam combination in a pediatric patient with hematologic malignancy.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2019;\n\t\t\t\t\t63(\n\t\t\t\t\t2):\n\t\t\t\t\te02463\u2013\n\t\t\t\t\t0218."},{"issue":"8","key":"i2331-348X-27-2-192-b20","series-title":"Pediatr Infect Dis J","first-page":"812","article-title":"Use of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age","volume":"38","year":"2019","unstructured":"Iosifidis\n              E,\n            \n            \n              Chorafa\n              E,\n            \n            \n              Agakidou\n              E,\n            \n          \n          .\n\t\t\t\t\tUse of ceftazidime-avibactam for the treatment of extensively drug-resistant or pan drug-resistant Klebsiella pneumoniae in neonates and children <5 years of age.\n\t\t\t\t\tPediatr Infect Dis J.\n\t\t\t\t\t2019;\n\t\t\t\t\t38(\n\t\t\t\t\t8):\n\t\t\t\t\t812\u2013\n\t\t\t\t\t815."},{"key":"i2331-348X-27-2-192-b21","series-title":"Infect Drug Resist","first-page":"1763","article-title":"Optimal management of complicated infections in the pediatric patient: the role and utility of ceftazidime\/avibactam","volume":"13","year":"2020","unstructured":"Bassetti\n              M,\n            \n            \n              Peghin\n              M,\n            \n            \n              Mesini\n              A,\n            \n            \n              Castagnola\n              E.\n            \n          \n          Optimal management of complicated infections in the pediatric patient: the role and utility of ceftazidime\/avibactam.\n\t\t\t\t\tInfect Drug Resist.\n\t\t\t\t\t2020;\n\t\t\t\t\t13:\n\t\t\t\t\t1763\u2013\n\t\t\t\t\t1773."},{"issue":"4","key":"i2331-348X-27-2-192-b22","series-title":"Antimicrob Agents Chemother","first-page":"2322","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems","volume":"58","year":"2014","unstructured":"Daikos\n              GL,\n            \n            \n              Tsaousi\n              S,\n            \n            \n              Tzouvelekis\n              LS,\n            \n          \n          .\n\t\t\t\t\tCarbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2014;\n\t\t\t\t\t58(\n\t\t\t\t\t4):\n\t\t\t\t\t2322\u2013\n\t\t\t\t\t2328."},{"issue":"4","key":"i2331-348X-27-2-192-b23","series-title":"Antimicrob Agents Chemother","first-page":"2108","article-title":"Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens","volume":"56","year":"2012","unstructured":"Qureshi\n              ZA,\n            \n            \n              Paterson\n              DL,\n            \n            \n              Potoski\n              BA,\n            \n          \n          .\n\t\t\t\t\tTreatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2012;\n\t\t\t\t\t56(\n\t\t\t\t\t4):\n\t\t\t\t\t2108\u2013\n\t\t\t\t\t2113."},{"issue":"7","key":"i2331-348X-27-2-192-b24","series-title":"Clin Infect Dis","first-page":"943","article-title":"Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy","volume":"55","year":"2012","unstructured":"Tumbarello\n              M,\n            \n            \n              Viale\n              P,\n            \n            \n              Viscoli\n              C,\n            \n          \n          .\n\t\t\t\t\tPredictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.\n\t\t\t\t\tClin Infect Dis.\n\t\t\t\t\t2012;\n\t\t\t\t\t55(\n\t\t\t\t\t7):\n\t\t\t\t\t943\u2013\n\t\t\t\t\t950."},{"issue":"9","key":"i2331-348X-27-2-192-b25","series-title":"Clin Microbiol Infect","first-page":"862","article-title":"Treating infections caused by carbapenemaseproducing Enterobacteriaceae","volume":"20","year":"2014","unstructured":"Tzouvelekis\n              LS,\n            \n            \n              Markogiannakis\n              A,\n            \n            \n              Piperaki\n              E,\n            \n          \n          .\n\t\t\t\t\tTreating infections caused by carbapenemaseproducing Enterobacteriaceae.\n\t\t\t\t\tClin Microbiol Infect.\n\t\t\t\t\t2014;\n\t\t\t\t\t20(\n\t\t\t\t\t9):\n\t\t\t\t\t862\u2013\n\t\t\t\t\t872."},{"key":"i2331-348X-27-2-192-b26","article-title":"Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities. WHO Guidelines Approved by the Guidelines Review Committee","year":"2017","unstructured":"Guidelines for the Prevention and Control of Carbapenem-Resistant Enterobacteriaceae, Acinetobacter baumannii and Pseudomonas aeruginosa in Health Care Facilities. WHO Guidelines Approved by the Guidelines Review Committee.\n\t\t\t\t\tGeneva;\n\t\t\t\t\t2017."},{"key":"i2331-348X-27-2-192-b27","unstructured":"U.S. Food and Drug Administration.\n          \n          Tygacil PI. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/205645s001lbl.pdf. Accessed March 28, 2019."},{"issue":"4","key":"i2331-348X-27-2-192-b28","series-title":"J Pediatr Pharmacol Ther","first-page":"304","article-title":"Levofloxacin use in the neonate: a case series","volume":"22","year":"2017","unstructured":"Newby\n              BD,\n            \n            \n              Timberlake\n              KE,\n            \n            \n              Lepp\n              LM,\n            \n          \n          .\n\t\t\t\t\tLevofloxacin use in the neonate: a case series.\n\t\t\t\t\tJ Pediatr Pharmacol Ther.\n\t\t\t\t\t2017;\n\t\t\t\t\t22(\n\t\t\t\t\t4):\n\t\t\t\t\t304\u2013\n\t\t\t\t\t313."},{"key":"i2331-348X-27-2-192-b29","series-title":"Minerva Pediatr","doi-asserted-by":"publisher","DOI":"10.23736\/S0026-4946.19.05640-8","article-title":"Early initiation of broad-spectrum antibiotics in premature infants [published online ahead of print November 11, 2019]","unstructured":"Asfour\n              S,\n            \n            \n              Al-Mouqdad\n              M.\n            \n          \n          Early initiation of broad-spectrum antibiotics in premature infants [published online ahead of print November 11, 2019].\n\t\t\t\t\tMinerva Pediatr.\n\t\t\t\t\t10.23736\/S0026-4946.19.05640-8"},{"issue":"6","key":"i2331-348X-27-2-192-b30","series-title":"Am J Infect Control","first-page":"e31","article-title":"Predictors for gut colonization of carbapenem-resistant Enterobacteriaceae in neonates in a neonatal intensive care unit","volume":"46","year":"2018","unstructured":"Singh\n              NP,\n            \n            \n              Choudhury\n              DD,\n            \n            \n              Gupta\n              K,\n            \n          \n          .\n\t\t\t\t\tPredictors for gut colonization of carbapenem-resistant Enterobacteriaceae in neonates in a neonatal intensive care unit.\n\t\t\t\t\tAm J Infect Control.\n\t\t\t\t\t2018;\n\t\t\t\t\t46(\n\t\t\t\t\t6):\n\t\t\t\t\te31\u2013\n\t\t\t\t\te35."},{"issue":"10","key":"i2331-348X-27-2-192-b31","series-title":"Antimicrob Agents Chemother","first-page":"6252","article-title":"Phase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients","volume":"60","year":"2016","unstructured":"Bradley\n              JS,\n            \n            \n              Armstrong\n              J,\n            \n            \n              Arrieta\n              A,\n            \n          \n          .\n\t\t\t\t\tPhase I study assessing the pharmacokinetic profile, safety, and tolerability of a single dose of ceftazidime-avibactam in hospitalized pediatric patients.\n\t\t\t\t\tAntimicrob Agents Chemother.\n\t\t\t\t\t2016;\n\t\t\t\t\t60(\n\t\t\t\t\t10):\n\t\t\t\t\t6252\u2013\n\t\t\t\t\t6259."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/2\/article-p192.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/meridian.allenpress.com\/jppt\/article-pdf\/27\/2\/192\/3108259\/i2331-348x-27-2-192.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/2\/article-p192.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/27\/2\/article-p192.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,15]],"date-time":"2025-05-15T20:35:58Z","timestamp":1747341358000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/27\/2\/article-p192.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":31,"journal-issue":{"issue":"2"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-27.2.192","relation":{},"ISSN":["1551-6776"],"issn-type":[{"value":"1551-6776","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}